New cocktail targets HER2-Positive bile duct cancer in small trial
NCT ID NCT06178445
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial is testing a combination of chemotherapy (gemcitabine/cisplatin) plus two targeted drugs (trastuzumab and pembrolizumab) as a first treatment for people with HER2-positive biliary tract cancer that cannot be removed by surgery. The study includes 24 participants and aims to see how many respond to the treatment within 6 months. It is active but no longer recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
gemcitabine, cisplatin, trastuzumab, and pembrolizumab
What this could lead to
If successful, this combination could offer a new first-line treatment option for people with HER2-positive biliary tract cancer, potentially improving response rates and survival.
What could go wrong
This is a small, early-phase (phase 2) trial with only 24 participants, so results may not apply to everyone. Combining multiple drugs also raises the risk of side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BILIARY TRACT CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Charité Universitätsmedizin
Berlin, Germany
-
Hämatologisch-Onkologische Praxis Eppendorf (HOPE)
Hamburg, Germany
-
Krankenhaus Nordwest (KHNW)
Frankfurt, Germany
-
LMU München
München, Germany
-
Medizinische Hochschule Hannover
Hanover, Germany
-
Universitätsklinikum Augsburg
Augsburg, Germany
-
Universitätsklinikum Freiburg
Freiburg im Breisgau, Germany
-
Universitätsklinikum Göttingen
Göttingen, Germany